The Oncology Institute, Inc. TOI Derivative Liabilities (Non-Current)
Derivative Liabilities (Non-Current) at other companies
Other financials
Where this comes from
Reported directly by The Oncology Institute, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DerivativeLiabilitiesNoncurrent.
The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about The Oncology Institute, Inc.'s derivative liabilities (non-current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is The Oncology Institute, Inc.'s derivative liabilities (non-current)?
- The Oncology Institute, Inc. (TOI) reported derivative liabilities (non-current) of $7.6M in Q1 2026.
- How has The Oncology Institute, Inc.'s derivative liabilities (non-current) changed year-over-year?
- The Oncology Institute, Inc.'s derivative liabilities (non-current) increased by 105.6% year-over-year, from $3.69M to $7.6M.
- What does derivative liabilities (non-current) mean?
- This represents the total fair value of derivative financial instruments that the company expects to settle beyond the next twelve months. These liabilities typically arise from hedging activities, embedded derivatives in debt instruments, or other complex financial contracts. Tracking this metric helps investors assess the company's long-term exposure to market risks such as interest rate or currency fluctuations.